Gossamer Bio (NASDAQ:GOSS) Trading 8.8% Higher – Time to Buy?

Gossamer Bio, Inc. (NASDAQ:GOSS) shares were up 8.8% during trading on Monday . The company traded as high as $2.56 and last traded at $2.48. Approximately 2,703,671 shares traded hands during trading, a decline of 41% from the average daily volume of 4,581,135 shares. The stock had previously closed at $2.28.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Barclays assumed coverage on Gossamer Bio in a report on Tuesday, January 27th. They set an “overweight” rating and a $9.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Gossamer Bio Price Performance

The stock’s 50 day moving average is $3.00 and its 200-day moving average is $2.65. The company has a market capitalization of $569.39 million, a P/E ratio of -3.57 and a beta of 1.93.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $13.29 million for the quarter, compared to analysts’ expectations of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. On average, equities research analysts anticipate that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Institutional Trading of Gossamer Bio

Large investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL raised its stake in Gossamer Bio by 7.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock valued at $132,000 after buying an additional 3,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Gossamer Bio by 24.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,964 shares of the company’s stock worth $74,000 after acquiring an additional 4,767 shares during the period. Drive Wealth Management LLC increased its position in Gossamer Bio by 52.7% during the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after acquiring an additional 8,797 shares during the last quarter. CWM LLC lifted its holdings in Gossamer Bio by 35.7% in the fourth quarter. CWM LLC now owns 33,957 shares of the company’s stock valued at $105,000 after acquiring an additional 8,940 shares during the period. Finally, Choreo LLC boosted its position in Gossamer Bio by 11.8% in the third quarter. Choreo LLC now owns 85,111 shares of the company’s stock worth $224,000 after purchasing an additional 9,000 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.